DRRX - Pendapatan operasional sadurunge ngurangi amortisasi DURECT

DURECT Corporation (DRRX) management effectively advances R&D by leveraging external investments. The absolute operating profit metric reflects cash flow dynamics, where the mark characterizes this parameter. DURECT Corporation is diversifying its pipeline by developing therapies for the skin and liver. Epigenetics patents and strict FDA oversight create significant barriers to entry for new market participants.

DRRX (DURECT) riwayat Bathi operasional EBITDA saka 04.07.2022 nganti 12.11.2026

DURECT (DRRX) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Bagan rega DURECT Corp|DRRX - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Kapitalisasi pasar DURECT|DRRX - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data ekuitas miturut neraca:

Aset Bersih saben Siji Saham DURECT|DRRX - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku durect.com|DRRX - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi DURECT Corporation|DRRX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang modal DURECT Corp|DRRX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku DURECT|DRRX - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan DURECT|Likuiditas darurat durect.com

- indikator pendapatan resik lan kelipatan nilai:

DRRX - Bathi resik|Bathi mangsa ngarep DURECT Corporation|DRRX - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep DURECT Corp|DRRX - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan DURECT|DRRX - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan DURECT|DRRX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan durect.com|DRRX - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep DURECT Corporation

Pambiji fundamental perusahaan:DRRX (DURECT Corporation)

The strong pricing power of DURECT Corporation (DRRX) in the hepatitis therapy segment makes the EBITDA chart a key tool for assessing the monetization of unique epigenetic control of gene expression. This metric isolates net cash flow from the impact of non-cash write-downs, allowing investors to differentiate real business growth from speculative stock price inflation through the analysis of this chart.

Pesaing DURECT Corporation (DRRX)

Arrowhead Corp - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Mirum Pharmaceuticals - Bathi operasional EBITDA|Pendapatan operasional sadurunge ngurangi amortisasi Dynavax Technologies Corp DVAX|ABUS (Arbutus Biopharma Corporation) - Bathi operasional sadurunge ngurangi amortisasi|IVA (Inventiva SA) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|GYRE (Gyre Corp) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Assembly Corp ASMB|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Galectin Therapeutics (GALT)|GNFT (genfit.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional EBITDA ALGS (Aligos Therapeutics, Inc.)|BIVI: Bathi operasional sadurunge amortisasi|GLMD: Bathi operasional sadurunge ngurangi amortisasi|NDRA - Bathi operasional EBITDA|hepionpharma.com (HEPA) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi